Letter by Martin et al Regarding Article, “Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial”
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.